This article was originally published in Pharmaceutical Approvals Monthly
Baxter/Alpha Therapeutics' Aralast is approved Dec. 23 as augmentation therapy in patients who have congenital deficiency of alpha-1 proteinase inhibitor with clinically evident emphysema. The only other A1-PI on the market, Bayer's Prolastin, has been experiencing supply problem
You may also be interested in...
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.